Trial Profile
A Study to Evaluate the Safety and Efficacy of Aprepitant (MK0869) for Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Aug 2013
Price :
$35
*
At a glance
- Drugs Aprepitant (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 01 Aug 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jan 2013 New trial record